Concert's hair loss product meets in Phase IIa, but with slower onset than Pfizer's

Concert Pharmaceuticals Inc. (NASDAQ:CNCE) reported Phase IIa data suggesting that its JAK inhibitor CTP-543 may have a later onset in treating alopecia areata than competing Phase IIa products from Pfizer Inc. (NYSE:PFE).

Twice-daily 8 mg CTP-543 met the primary endpoint of

Read the full 402 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE